A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Terminated · Phase 2 · NCT04875975
Conditions: Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
At a glance
- Research payments reported, 2025
- $27,362
- U.S. investigators named
- 2
- Sites paid
- 3
- Planned or actual enrollment
- 12
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- Rozanolixizumab (drug), Placebo (drug)
- Dates
- Started 2021-09-27; completion 2024-04-26
- Results posted
- Yes
The purpose of the study is to assess the efficacy of rozanolixizumab as measured by seizure freedom, change in cognitive function, use of rescue medication, onset of seizure freedom and to assess safety and tolerability.
From ClinicalTrials.gov, last updated 2025-05-31. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $27,362 in research payments for this study in 2025 (3 payments).
Products named: Rystiggo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Cleveland Clinic, OH $16,350
- New York University $8,262
- Brigham and Women's Hospital, MA $2,750
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.